Barriers and enablers for deprescribing among older, multimorbid patients with polypharmacy: an explorative study from Switzerland.
And relationship
Conservatism
Devaluation
Patient involvement
The burden of treatment
Trust
Journal
BMC family practice
ISSN: 1471-2296
Titre abrégé: BMC Fam Pract
Pays: England
ID NLM: 100967792
Informations de publication
Date de publication:
14 05 2019
14 05 2019
Historique:
received:
28
01
2019
accepted:
29
04
2019
entrez:
16
5
2019
pubmed:
16
5
2019
medline:
26
2
2020
Statut:
epublish
Résumé
Polypharmacy is an increasing problem, leading to increased morbidity and mortality, especially in older, multimorbid patients. Consequently, there is a need for reduction of polypharmacy. The aim of this study was to explore attitudes, beliefs, and concerns towards deprescribing among older, multimorbid patients with polypharmacy who chose not to pursue at least one of their GP's offers to deprescribe. Exploratory study using telephone interviews among patients of a cluster-randomized study in Northern Switzerland. The interview included a qualitative part consisting of questions in five pre-defined key areas of attitudes, beliefs, and concerns about deprescribing and an open explorative question. The quantitative part consisted of a rating of pre-defined statements in these areas. Twenty-two of 87 older, multimorbid patients with polypharmacy, to whom their GP offered a drug change, did not pursue all offers. Nineteen of these 22 were interviewed by telephone. The 19 patients were on average 76.9 (SD 10.0) years old, 74% female, and took 8.9 (SD 2.6) drugs per day. Drugs for acid-related disorders, analgesics and anti-inflammatory drugs were the three most common drug groups where patient involvement and the shared-decision-making (SDM) process led to the joint decision to not pursue the GPs offer. Eighteen of 19 patients fully trusted their GP, 17 of 19 participated in SDM even before this study and 8 of 19 perceived polypharmacy as a substantial burden. Conservatism/inertia and fragmented medical care were the main barriers towards deprescribing. No patient felt devalued as a consequence of the deprescribing offer. Our exploratory findings were supported by patients' ratings of predefined statements. We identified patient involvement in deprescribing and coordination of care as key issues for deprescribing among older multimorbid patients with polypharmacy. GPs concerns regarding patients' devaluation should not prevent them from actively discussing the reduction of drugs. ISRCTN16560559 .
Sections du résumé
BACKGROUND
Polypharmacy is an increasing problem, leading to increased morbidity and mortality, especially in older, multimorbid patients. Consequently, there is a need for reduction of polypharmacy. The aim of this study was to explore attitudes, beliefs, and concerns towards deprescribing among older, multimorbid patients with polypharmacy who chose not to pursue at least one of their GP's offers to deprescribe.
METHODS
Exploratory study using telephone interviews among patients of a cluster-randomized study in Northern Switzerland. The interview included a qualitative part consisting of questions in five pre-defined key areas of attitudes, beliefs, and concerns about deprescribing and an open explorative question. The quantitative part consisted of a rating of pre-defined statements in these areas.
RESULTS
Twenty-two of 87 older, multimorbid patients with polypharmacy, to whom their GP offered a drug change, did not pursue all offers. Nineteen of these 22 were interviewed by telephone. The 19 patients were on average 76.9 (SD 10.0) years old, 74% female, and took 8.9 (SD 2.6) drugs per day. Drugs for acid-related disorders, analgesics and anti-inflammatory drugs were the three most common drug groups where patient involvement and the shared-decision-making (SDM) process led to the joint decision to not pursue the GPs offer. Eighteen of 19 patients fully trusted their GP, 17 of 19 participated in SDM even before this study and 8 of 19 perceived polypharmacy as a substantial burden. Conservatism/inertia and fragmented medical care were the main barriers towards deprescribing. No patient felt devalued as a consequence of the deprescribing offer. Our exploratory findings were supported by patients' ratings of predefined statements.
CONCLUSION
We identified patient involvement in deprescribing and coordination of care as key issues for deprescribing among older multimorbid patients with polypharmacy. GPs concerns regarding patients' devaluation should not prevent them from actively discussing the reduction of drugs.
TRIAL REGISTRATION
ISRCTN16560559 .
Identifiants
pubmed: 31088397
doi: 10.1186/s12875-019-0953-4
pii: 10.1186/s12875-019-0953-4
pmc: PMC6518702
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
64Références
Eur J Gen Pract. 2018 Dec;24(1):9-18
pubmed: 29199486
Age Ageing. 2015 Mar;44(2):213-8
pubmed: 25324330
BMC Fam Pract. 2018 Jul 9;19(1):110
pubmed: 29986668
Aliment Pharmacol Ther. 2004 Apr 15;19(8):917-22
pubmed: 15080853
BMC Geriatr. 2016 Jan 15;16:15
pubmed: 26767619
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Praxis (Bern 1994). 2014 Mar 12;103(6):317-22
pubmed: 24618310
Age Ageing. 2016 Mar;45(2):201-9
pubmed: 26755524
PLoS One. 2014 Aug 19;9(8):e105425
pubmed: 25136981
J Am Geriatr Soc. 2013 Sep;61(9):1508-14
pubmed: 24028356
Drugs Aging. 2018 Jan;35(1):61-71
pubmed: 29335932
Br J Gen Pract. 2016 Aug;66(649):e552-60
pubmed: 27266865
Chronic Illn. 2006 Jun;2(2):133-42
pubmed: 17175656
Ann Fam Med. 2017 Jul;15(4):341-346
pubmed: 28694270
BMC Fam Pract. 2018 Jan 15;19(1):17
pubmed: 29334913
Age Ageing. 2008 Mar;37(2):138-41
pubmed: 18349010
BMJ. 2016 Jun 03;353:i2893
pubmed: 27260319
J Eval Clin Pract. 2012 Apr;18(2):409-13
pubmed: 21087373
Age Ageing. 2017 Mar 1;46(2):291-299
pubmed: 27836856
BMC Fam Pract. 2013 Feb 09;14:20
pubmed: 23394162
Dtsch Arztebl Int. 2010 Aug;107(31-32):543-51
pubmed: 20827352
PLoS One. 2012;7(3):e33236
pubmed: 22438900
Drugs Aging. 2016 Dec;33(12):913-928
pubmed: 27785734
Trials. 2016 Jan 29;17:57
pubmed: 26822311
Clin Pharmacol Ther. 2011 Jun;89(6):845-54
pubmed: 21508941
BMJ Open. 2014 Dec 08;4(12):e006544
pubmed: 25488097
Isr Med Assoc J. 2007 Jun;9(6):430-4
pubmed: 17642388
Qual Health Res. 2018 Nov;28(13):2094-2101
pubmed: 30043686
Br J Gen Pract. 2003 Aug;53(493):607-13
pubmed: 14601336
BMC Fam Pract. 2016 Nov 3;17(1):149
pubmed: 27809865
Br J Clin Pharmacol. 2014 Jun;77(6):1073-82
pubmed: 24428591
Drugs Aging. 2005;22(1):69-82
pubmed: 15663350
BMC Fam Pract. 2017 Jun 6;18(1):70
pubmed: 28587644
J Gen Intern Med. 2007 Aug;22(8):1094-100
pubmed: 17492325
Patient Prefer Adherence. 2018 Jun 11;12:1003-1005
pubmed: 29928115
BMC Fam Pract. 2016 Nov 5;17(1):152
pubmed: 27814691
Drugs Aging. 2010 Jun 1;27(6):435-49
pubmed: 20524704
BMC Fam Pract. 2018 Jul 18;19(1):113
pubmed: 30021528
Medsurg Nurs. 2012 May-Jun;21(3):129-32; quiz 133
pubmed: 22866431
N Engl J Med. 2011 Nov 24;365(21):2002-12
pubmed: 22111719
Br J Clin Pharmacol. 2016 Sep;82(3):583-623
pubmed: 27077231
BMJ Open. 2017 May 4;7(4):e015959
pubmed: 28473524
BMC Fam Pract. 2015 Feb 07;16:16
pubmed: 25881287
Drugs Aging. 2008;25(12):1061-75
pubmed: 19021304
Br J Gen Pract. 2017 Jul;67(660):e507-e518
pubmed: 28533200
Drugs Aging. 2009;26(6):475-82
pubmed: 19591522
BMC Fam Pract. 2012 Jul 09;13:56
pubmed: 22697490
BMC Fam Pract. 2018 Jul 28;19(1):131
pubmed: 30055583
Drugs Aging. 2013 Oct;30(10):793-807
pubmed: 23912674
Drugs Aging. 2013 Jul;30(7):561-8
pubmed: 23553511
Curr Clin Pharmacol. 2015;10(3):168-77
pubmed: 26338170
Eur J Clin Pharmacol. 2011 Nov;67(11):1175-88
pubmed: 21584788
Eur J Gen Pract. 2018 Dec;24(1):120-124
pubmed: 29202616
Trials. 2015 Aug 26;16:380
pubmed: 26306691
BMC Fam Pract. 2018 May 2;19(1):47
pubmed: 29720091
Patient Prefer Adherence. 2017 Aug 22;11:1451-1458
pubmed: 28860728